February 28, 2015 4:04 PM ET

Healthcare Providers and Services

Company Overview of City Of Hope

Company Overview

City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.

1500 East Duarte Road

Duarte, CA 91010

United States

Founded in 1913



Key Executives for City Of Hope

Chief Executive Officer and President
Chief Financial Officer
Age: 51
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2014.

City Of Hope Key Developments

Larry Kwak Will Join City of Hope to Head One of Six Cornerstone Centers in the Institution's

City Of Hope announced that Larry W. Kwak, M.D., Ph.D., will join City of Hope in a key leadership role within the institution's new Hematologic Malignancies and Stem Cell Transplantation Institute. As director of the Toni Stephenson Lymphoma Center, Kwak will shape the next generation of research and treatments for all types of lymphoma. Kwak joins City of Hope from M.D. Anderson Cancer Center in Houston, where he served as chairman of the Department of Lymphoma and Myeloma and as co-director of the Center for Cancer Immunology Research. At City of Hope, he will head one of six cornerstone centers in the institution's recently launched hematologic malignancies institute, setting scientific priorities and guiding the development of new approaches to treating lymphoma and related diseases, especially those involving immune-based treatments. Kwak will also serve in the dual leadership role of inaugural associate director for developmental therapeutics and translational research for City of Hope's National Cancer Institute-designated comprehensive cancer center and hold the title of the Dr. Michael Friedman Professor for Translational Medicine.

Guido Marcucci Joins City of Hope in Leadership Role

Guido Marcucci has joined City of Hope in a key leadership role within the institution’s new Hematologic Malignancies and Stem Cell Transplantation Institute. As Director of the Gehr Family Center for Leukemia Research and as Chief of the Division of Hematopoietic Stem Cell and Leukemia Research, Marcucci will guide research into improved treatments, even cures, for leukemia and other hematologic malignancies. Marcucci, who will also serve as a professor of Hematology & Hematopoietic Cell Transplantation, joins City of Hope from Ohio State University, where he was a professor of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, and Pharmaceutics in the Division of Hematology at the university’s Comprehensive Cancer Center. At City of Hope, he will head one of six cornerstone centers in the institution’s recently launched hematologic institute, setting scientific priorities and guiding the development of new approaches to treating leukemia and related diseases, especially those involving hematopoietic stem cell transplantation.

Trovagene and City of Hope Collaborate to Monitor EGFR Mutational Status in Lung Cancer Patients

Trovagene, Inc. announced that it has entered into a clinical collaboration with City of Hope to conduct studies to determine the clinical utility of detecting and monitoring EGFR mutations in lung cancer patients using Trovagene's Precision Cancer MonitoringSM platform. The clinical study is expected to enroll 75 patients with lung cancer. Primary objectives of the study include evaluating concordance between urinary circulating tumor DNA (ctDNA), blood ctDNA, and tumor tissue for determining EGFR mutational status. Additionally, the study investigators will evaluate the quantitative and qualitative performance of longitudinal EGFR mutation monitoring using both urine and blood specimens, as they relate to response to therapy over time. Exploratory objectives include evaluating the feasibility of identifying the TKI-resistant mutation, T790M, in urinary and blood ctDNA at the time of progression.

Similar Private Companies By Industry

Company Name Region
BreatheAmerica, Inc. United States
MSD Consumer Products Inc. United States
MiraMed Global Services, Inc. United States
Medical Equipment Services, Inc. United States
PopHealthCare L.L.C. United States

Recent Private Companies Transactions

Private Placement
November 26, 2014
Luminat, LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact City Of Hope, please visit www.cityofhope.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.